WT1 splicing alterations in Wilms' tumors

Clinical Cancer Research

Volumn 6, Issue 10, 2000, Pages 3957-3965

  Baudry, Dominique ^a   Hamelin, Muriel ^a   Cabanis, Marie Odile ^a   Fournet, Jean Christophe ^b   Tournade, Marie France ^c   Sarnacki, Sabine ^b   Junien, Claudine ^a   Jeanpierre, Cécile ^a  

^a INSERM   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER GENETICS; GENE MUTATION; HUMAN; HUMAN TISSUE; KIDNEY DEVELOPMENT; NEPHROBLASTOMA; PRIORITY JOURNAL; RNA ANALYSIS; RNA SPLICING;

ALTERNATIVE SPLICING; BLOTTING, SOUTHERN; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; EXONS; GERM-LINE MUTATION; HUMANS; KIDNEY; MUTATION; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; WILMS TUMOR; WT1 PROTEINS;

EID: 0033760539     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus
2. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping
3. The candidate Wilms' tumour gene is involved in genitourinary development
4. WT1 is required for early kidney development
5. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins
6. Antagonism of WT1 activity by protein self-association
7. Truncated WT1 mutants alter the subnuclear localization of the wild type protein
8. An RNA recognition motif in Wilms' tumour protein (WT1) revealed by structural modelling
9. Overlapping RNA and DNA binding domains of the WT1 tumor suppressor gene product
10. Alternative splicing and genomic structure of the Wilms' tumor gene WT1
11. RNA editing in the Wilms' tumor susceptibility gene, WT1
12. A non-AUG translational initiation event generates novel WT1 isoforms
13. Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties
14. The Wilms' tumor suppressor WT1: Approaches to gene function
15. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1
16. The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene
17. Repression of Pax-2 by WT1 during normal kidney development
18. The Wilms' tumor suppressor gene WT1 is negatively auto-regulated
19. Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition
20. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin
21. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing
22. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes
23. Presence of WT1, the Wilm's tumor suppressor gene product, in nuclear poly(A)(+) ribonucleoprotein
24. Donor splice-site mutations in WT1 are responsible for Frasier syndrome
25. Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/-KTS splice isoforms
26. Products of alternative spliced transcripts of the Wilms' tumor suppressor gene, WT1, have altered DNA binding specificity and regulate transcription in different ways
27. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Mullerian-inhibiting substance, and the androgen receptor
28. 1 phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes
29. Differentially spliced exon 5 of the Wilms' tumor gene WT1 modifies gene function
30. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis
31. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene
32. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells
33. Wilms' tumor 1-KTS isoforms induce p53-independent apoptosis that can be partially rescued by expression of the epidermal growth factor receptor or the insulin receptor
34. The evolution of WT1 sequence and expression pattern in the vertebrates
35. Identification of constitutional WT1 mutations in patients with isolated diffuse mesangial sclerosis (IDMS) and analysis of genotype-phenotype correlations using a computerized mutation database
36. Infrequent mutation of the WT1 gene in 77 Wilms' tumors
37. Fine structure analysis of the WT1 gene in sporadic Wilms tumors
38. Wilms tumor genetics
39. WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant
40. Splicing of exon 5 in the WT1 gene is disrupted in Wilms' tumours
41. Analysis of possible abnormal WT1 RNA processing in primary Wilms tumors
42. Imbalanced expression of functionally different WT1 isoforms may contribute to sporadic unilateral Wilms' tumor
43. Nonsense-mediated mRNA decay in health and disease
44. The expression pattern of Wilms' tumour gene (WT1) product in normal tissues and paediatric renal tumours
45. Expression of the Wilms' tumour gene WT1 in the developing human and in paediatric renal tumours: An immunohistochemical study
46. Expression of WT1 in pediatric small cell tumors: Report of two cases with a possible mesothelial origin
47. Histopathology and prognosis of Wilms' tumor
48. Correlations of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology
49. Loss of WT1 function leads to ectopic myogenesis in Wilms' tumour
50. Identification of differential methylation of the WT1 antisense regulatory region and relaxation of imprinting in Wilms' tumor
51. Differential splicing of exon 5 of the Wilms tumour (WT1) gene
52. Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer